MEPERIDINE HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Meperidine Hydrochloride patents expire, and when can generic versions of Meperidine Hydrochloride launch?
Meperidine Hydrochloride is a drug marketed by Abbott, Baxter Hlthcare, Igi Labs Inc, Intl Medication, Parke Davis, Watson Labs, West-ward Pharms Int, Hikma, Barr, Duramed Pharms Barr, Epic Pharma Llc, Genus, Specgx Llc, Strides Pharma, Sun Pharm Inds Inc, Sun Pharm Industries, Wyeth Ayerst, Hospira, and Icu Medical Inc. and is included in forty-two NDAs.
The generic ingredient in MEPERIDINE HYDROCHLORIDE is meperidine hydrochloride. There are six drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the meperidine hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Meperidine Hydrochloride
A generic version of MEPERIDINE HYDROCHLORIDE was approved as meperidine hydrochloride by HIKMA on January 30th, 1985.
Summary for MEPERIDINE HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 19 |
NDAs: | 42 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 45 |
Clinical Trials: | 69 |
Patent Applications: | 2,430 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MEPERIDINE HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for MEPERIDINE HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Tanta University | N/A |
Wonkwang University Hospital | N/A |
Astana Medical University | N/A |
Pharmacology for MEPERIDINE HYDROCHLORIDE
Drug Class | Opioid Agonist |
Mechanism of Action | Full Opioid Agonists |